Overview A Study of LXR015-1 in HIV-Infected Patients Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients. Phase: Phase 1 Details Lead Sponsor: LXR Biotechnology